Primary Resistance to Brigatinib in a Patient with Lung Adenocarcinoma Harboring ALK G1202R Mutation and LIPI-NTRK1 Rearrangement

PURPOSE: Anaplastic lymphoma kinase (ALK) inhibitors have transformed the management of non-small-cell lung cancer (NSCLC) patients with ALK gene rearrangement. This paper reports a new resistance mechanism to a second-generation ALK inhibitor, brigatinib. CASE REPORT: A 43-year-old woman who had no...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Zhiwei, Huang, Xuewu, Xie, Biyuan, Xie, Wenzhuan, Huang, Mengli, Lin, Lizhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250292/
https://www.ncbi.nlm.nih.gov/pubmed/32547089
http://dx.doi.org/10.2147/OTT.S249652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250292/
https://www.ncbi.nlm.nih.gov/pubmed/32547089
http://dx.doi.org/10.2147/OTT.S249652

Ejemplares similares